Matthias Ghidossi, founder of Swiss Cannabinoid, has been working for years to cultivate his own terpene and cannabinoid-rich crops. Through a science-based approach, he surveyed thousands of varietals. During his quest in 2016, it became clear that the varietal of choice should not only be terpene-focused, but also CBG dominant. In fact, at that time he selected his first CBG variety. Working with several European geneticists and a Swiss pharmaceutical company on trials, he landed on Matterhorn CBG.

In 2019 he registered Matterhorn (Perugina) CBG at CPVO Europe. 

“CBG is a cannabinoid we chose to focus on due to its powerful efficacy in early trials. Over the past few years, more and more research has been conducted to understand the value of CBG. The early results of clinical testing in Europe are creating a lot of excitement in the fields of science and medicine,” said Matthias Ghidossi.